Showing 20 of 33 recruiting trials for “aggressive-nk-cell-leukemia”
Enrolling by InvitationNCT07474051 ↗
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
👨⚕️ Mengyang Di, MD, PhD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Dec 2025View details ↗
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
👨⚕️ Christopher J Melani, ECOG-ACRIN Cancer Research Group📍 70 sites📅 Started Oct 2025View details ↗
Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
👨⚕️ Dehui Zou, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started May 2025View details ↗
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
👨⚕️ Yazeed Sawalha, Ohio State University Comprehensive Cancer Center📍 2 sites📅 Started Apr 2025View details ↗
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
👨⚕️ Jennifer Lue, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Dec 2024View details ↗
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
SynKIR-310 for Relapsed/Refractory B-NHL
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
RecruitingNCT06550427 ↗
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
👨⚕️ Tai-Chung Huang, Ph.D, National Taiwan University Hospital📍 1 site📅 Started Aug 2024View details ↗
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
👨⚕️ Breffni Hannon, MB BCh BAO, MMedSci, MCFP, Princess Margaret Cancer Centre📍 1 site📅 Started Jul 2024View details ↗
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
👨⚕️ Catherine THIEBLEMONT, Prof. Dr., Hôpital Saint-Louis📍 13 sites📅 Started Jun 2024View details ↗
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
👨⚕️ Grzegorz S Nowakowski, Academic and Community Cancer Research United📍 6 sites📅 Started Jan 2024View details ↗
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →